- Novartis talks up potential blockbusters
- Stockwatch: biotech stock propagandists, beware!
- Post-Zohydro, Zogenix shifts focus to rare epilepsy, schizophrenia
- Naurex leads VC funding surge with $80 Series C
- Interview: Quintiles India CEO on green shoots, digital patients & white noise
- The EMA at 20: CAT chair on where all the advanced therapies are, and Holoclar, the bright light of stem cell therapy